OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
REDWOOD CITY, Calif., Oct. 26, 2016 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell (“anti-CSC”) and immuno-oncology product candidates, will announce financial results for the quarter ended September 30, 2016 on Tuesday, November 1, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review third quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID#22966202. The webcast of the conference call will be accessible in the Investor Relations section of the OncoMed website: http://www.oncomed.com. A press release detailing third quarter results will be posted to the OncoMed website shortly before the conference call.
The web broadcast of the conference call will be available for replay through December 31, 2016 via the OncoMed website. An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (I/O#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).
Additional information can be found at the company's website: www.oncomed.com.
Contact:
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals
[email protected]
(650) 995-8373
